Anti-apoptotic actions of ppar-γ against ischemic stroke

Molecular Neurobiology

Volumn 41, Issue 2-3, 2010, Pages 180-186

  Fong, Wen Hsuan ^a   Tsai, Hsin Da ^a   Chen, Yu Chang ^a   Wu, Jui Sheng ^a   Lin, Teng Nan ^a  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

14 3 3e; 15d PGJ2; Bad; Bcl 2; Fatty acids; ROS; Rosiglitazone

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 4,4' ISOPROPYLIDENEDIPHENOL; CATALASE; LG 100641; MIFOBATE; PD 068235; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PIOGLITAZONE; PROTEIN 14 3 3; PROTEIN BAD; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; ROSIGLITAZONE; SUPEROXIDE DISMUTASE; TROGLITAZONE; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; LIGAND; YWHAE PROTEIN, HUMAN;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; BRAIN INFARCTION; BRAIN ISCHEMIA; CONFERENCE PAPER; DRUG ACTIVITY; DRUG MECHANISM; GENE; HEART WORK; HEMODILUTION; HUMAN; LIVER TOXICITY; NEUROPROTECTION; NONHUMAN; PERIPHERAL EDEMA; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; SIDE EFFECT; WEIGHT GAIN; AGONISTS; ANIMAL; GENETICS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; STROKE;

14-3-3 PROTEINS; ANIMALS; APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; BRAIN ISCHEMIA; HUMANS; HYPOGLYCEMIC AGENTS; LIGANDS; PPAR GAMMA; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; STROKE; THIAZOLIDINEDIONES;

EID: 77955085757     PISSN: 08937648     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12035-010-8103-y     Document Type: Conference Paper

References (63)

1. Nuclear Receptors Nomenclature Committee (1999) A unified nomenclature system for the nuclear receptor superfamily. Cell 97:161-163
2. Issemann I, Green S (1990) Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347:645-650
3. Collino M, Patel NS, Thiemermann C (2008) PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfu-sion injury. Ther Adv Cardiovasc Dis 2:179-197
4. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W (1992) Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 68:879-887
5. Hamblin M, Chang L, Fan Y, Zhang J, Chen YE (2009) PPARs and the cardiovascular system. Antioxid Redox Signal 11:1415-1452
6. Berger J, Moller DE (2002) The mechanisms of action of PPARs. Annu Rev Med 53:409-435
7. Chandra V, Huang P, Hamuro Y, Raghuram S, Wang Y, Burris TP, Rastinejad F (2008) Structure of the intact PPAR-γ-RXR-α nuclear receptor complex on DNA. Nature 456:350-356
8. Willson TM, Lambert MH, Kliewer SA (2001) Peroxisome proliferator- activated receptor gamma and metabolic disease. Annu Rev Biochem 70:341-367
9. Heneka MT, Landreth GE (2007) PPARs in the brain. Biochim Biophys Acta 1771:1031-1045
10. Pialat JB, Cho TH, Beuf O, Joye E, Moucharrafie S, Langlois JB, Nemoz C, Janier M, Berthezene Y, Nighoghossian N, Desvergne B, Wiart M (2007) MRI monitoring of focal cerebral ischemia in peroxisome proliferator-activated receptor (PPAR)-deficient mice. NMR Biomed 20:335-342
11. Wu JS, Cheung WM, Tsai YS, Chen YT, Fong WH, Tsai HD, Chen YC, Liou JY, Shyue SK, Chen JJ, Chen YE, Maeda N, Wu KK, Lin TN (2009) Ligand-activated peroxisome proliferator-activated receptor-gamma protects against ischemic cerebral infarction and neuronal apoptosis by 14-3-3 epsilon upregulation. Circulation 119:1124-1134
12. Zhu Y, Qi C, Korenberg JR, Chen XN, Noya D, Rao MS, Reddy JK (1995) Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: alternative promoter use and different splicing yield two mPPAR gamma isoforms. Proc Natl Acad Sci USA 92:7921-7925
13. Zhou J, Wilson KM, Medh JD (2002) Genetic analysis of four novel peroxisome proliferator activated receptor-gamma splice variants in monkey macrophages. Biochem Biophys Res Commun 293:274-283
14. Chen Y, Jimenez AR, Medh JD (2006) Identification and regulation of novel PPAR-gamma splice variants in human THP-1 macrophages. Biochim Biophys Acta 1759:32-43
15. Villacorta L, Schopfer FJ, Zhang J, Freeman BA, Chen YE (2009) PPARgamma and its ligands: therapeutic implications in cardiovascular disease. Clin Sci (Lond) 116:205-218
16. Bell-Parikh LC, Ide T, Lawson JA, McNamara P, Reilly M, FitzGerald GA (2003) Biosynthesis of 15-deoxy-delta12, 14-PGJ2 and the ligation of PPARgamma. J Clin Invest 112:945-955
17. Schopfer FJ, Lin Y, Baker PR, Cui T, Garcia-Barrio M, Zhang J, Chen K, Chen YE, Freeman BA (2005) Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand. Proc Natl Acad Sci USA 102:2340-2345
18. Bazan NG (1976) Free arachidonic acid and other lipids in the nervous system during early ischemia and after electroshock. Adv Exp Med Biol 72:317-335
19. Chan PH, Fishman RA, Longar S, Chen S, Yu A (1985) Cellular and molecular effects of polyunsaturated fatty acids in brain ischemia and injury. Prog Brain Res 63:227-235
20. Hsu CY, Liu TH, Xu J, Hogan EL, Chao J, Sun G, Tai HH, Beckman JS, Freeman BA (1989) Arachidonic acid and its metabolites in cerebral ischemia. Ann NY Acad Sci 559:282-295
21. Sun GY, Horrocks LA (1968) The fatty acid and aldehyde composition of the major phospholipids of mouse brain. Lipids 3:79-83
22. Wu JS, Lin TN, Wu KK (2009) Rosiglitazone and PPAR-gamma overexpression protect mitochondrial membrane potential and prevent apoptosis by upregulating anti-apoptotic Bcl-2 family proteins. J Cell Physiol 220:58-71
23. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270:12953-12956
24. Rubenstrunk A, Hanf R, Hum DW, Fruchart JC, Staels B (2007) Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta 1771:1065-1081
25. Feinstein DL, Spagnolo A, Akar C, Weinberg G, Murphy P, Gavrilyuk V, Dello Russo C (2005) Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochem Pharmacol 70:177-188
26. 2: the anti-inflammatory prostaglandin? Clin Immunol 114:100-109
27. Shimizu M, Yamashita D, Yamaguchi T, Hirose F, Osumi T (2006) Aspects of the regulatory mechanisms of PPAR functions: analysis of a bidirectional response element and regulation by sumoylation. Mol Cell Biochem 286:33-42
28. 2 protects brain from ischemia-reperfusion injury. Arterioscler Thromb Vasc Biol 26:481-487
29. Liu HR, Tao L, Gao E, Lopez BL, Christopher TA, Willette RN, Ohlstein EH, Yue TL, Ma XL (2004) Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion. Cardiovasc Res 62:135-144
30. Shimazu T, Inoue I, Araki N, Asano Y, Sawada M, Furuya D, Nagoya H, Greenberg JH (2005) A peroxisome proliferator-activated receptor-γ agonist reduces infarct size in transient but not in permanent ischemia. Stroke 36:353-359
31. Sundararajan S, Gamboa JL, Victor NA, Wanderi EW, Lust WD, Landreth GE (2005) Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia. Neurosci 130:685-696
32. Yue TL, Chen J, Bao W, Narayanan PK, Bril A, Jiang W, Lysko PG, Gu JL, Boyce R, Zimmerman DM, Hart TK, Buckingham RE, Ohlstein EH (2001) In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone. Circulation 104:2588-2594
33. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM (2001) PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nature Med 7:48-52
34. Jiang C, Ting AT, Seed B (1998) PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82-86
35. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK (1998) The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391:79-82
36. Bordet R, Ouk T, Petrault O, Gelé P, Gautier S, Laprais M, Deplanque D, Duriez P, Staels B, Fruchart JC, Bastide M (2006) PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans 34:1341-1346
37. Culman J, Zhao Y, Gohlke P, Herdegen T (2007) PPAR-gamma: therapeutic target for ischemic stroke. Trends Pharmacol Sci 28:244-249
38. Giaginis C, Tsourouflis G, Theocharis S (2008) Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands: novel pharmacological agents in the treatment of ischemia reperfusion injury. Curr Mol Med 8:562-579
39. Kapadia R, Yi JH, Vemuganti R (2008) Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci 13:1813-1826
40. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, Koder A, Evans RM (1999) PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 4:585-595
41. Tsai YS, Kim HJ, Takahashi N, Kim HS, Hagaman JR, Kim JK, Maeda N (2004) Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARgamma. J Clin Invest 114:240-249
42. Zhao X, Strong R, Zhang J, Sun G, Tsien JZ, Cui Z, Grotta JC, Aronowski J (2009) Neuronal PPARgamma deficiency increases susceptibility to brain damage after cerebral ischemia. J Neurosci 29:6186-6195
43. Schock SC, Xu J, Duquette PM, Qin Z, Lewandowski AJ, Rai PS, Thompson CS, Seifert EL, Harper ME, Chen HH (2008) Rescue of neurons from ischemic injury by peroxisome proliferator-activated receptor-gamma requires a novel essential cofactor LMO4. J Neurosci 28:12433-12444
44. Hengartner MO (2000) The biochemistry of apoptosis. Nature 407:770-776
45. Kerr JF, Wyllie AH, Currie AR (1972) Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26:239-257
46. Youle RJ, Strasser A (2008) The Bcl-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9:47-59
47. Mehta SL, Manhas N, Raghubir R (2007) Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res Rev 54:34-66
48. Fuenzalida K, Quintanilla R, Ramos P, Piderit D, Fuentealba RA, Martinez G, Inestrosa NC, Bronfman M (2007) Peroxisome proliferator-activated receptor gamma up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis. J Biol Chem 282:37006-37015
49. Lin H, Lin TN, Cheung WM, Nian GM, Tseng PH, Chen SF, Chen JJ, Shyue SK, Liou JY, Wu CW, Wu KK (2002) Cyclooxygenase-1 and bicistronic cyclooxygenase-1/prostacyclin synthase gene transfer protect against ischemic cerebral infarction. Circulation 105:1962-1969
50. Wang YL, Frauwirth KA, Rangwala SM, Lazar MA, Thompson CB (2002) Thiazolidinedione activation of peroxisome proliferator-activated receptor gamma can enhance mitochondrial potential and promote cell survival. J Biol Chem 277:31781-31788
51. Lim S, Jin CJ, Kim M, Chung SS, Park HS, Lee IK, Lee CT, Cho YM, Lee HK, Park KS (2006) PPARgamma gene transfer sustains apoptosis, inhibits vascular smooth muscle cell proliferation, and reduces neointima formation after balloon injury in rats. Arte-rioscler Thromb Vasc Biol 26:808-813
52. Pérez-Ortiz JM, Tranque P, Vaquero CF, Domingo B, Molina F, Calvo S, Jordán J, Ceña V, Llopis J (2004) Glitazones differentially regulate primary astrocyte and glioma cell survival. Involvement of reactive oxygen species and peroxisome proliferator-activated receptor-gamma. J Biol Chem 279:8976-8985
53. Shiau CW, Yang CC, Kulp SK, Chen KF, Chen CS, Huang JW, Chen CS (2005) Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma. Cancer Res 65:1561-1569
54. Calabrese EJ, Baldwin LA (2001) U-shaped dose-responses in biology, toxicology, and public health. Annu Rev Public Health 22:15-33
55. Calabrese EJ (2008) Drug therapies for stroke and traumatic brain injury often display U-shaped dose responses: occurrence, mechanisms, and clinical implications. Crit Rev Toxicol 38:557-577
56. Doonan F, Wallace DM, O'Driscoll C, Cotter TG (2009) Rosiglitazone acts as a neuroprotectant in retinal cells via up-regulation of sestrin-1 and SOD-2. J Neurochem 109:631-643
57. Girnun GD, Domann FE, Moore SA, Robbins ME (2002) Identification of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter. Mol Endocrinol 16:2793-2801
58. Hwang J, Kleinhenz DJ, Rupnow HL, Campbell AG, Thulé PM, Sutliff RL, Hart CM (2007) The PPARgamma ligand, rosiglita-zone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice. Vascul Pharmacol 46:456-462
59. Zhao X, Zhang Y, Strong R, Grotta JC, Aronowski J (2006) 15d-Prostaglandin J2 activates peroxisome proliferator-activated receptor-gamma, promotes expression of catalase, and reduces inflammation, behavioral dysfunction, and neuronal loss after intracerebral hemorrhage in rats. J Cereb Blood Flow Metab 26:811-820
60. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME (1997) Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91:231-241
61. Lin CY, Gurlo T, Haataja L, Hsueh WA, Butler PC (2005) Activation of peroxisome proliferator-activated receptor-gamma by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3′-kinase-dependent pathway. J Clin Endocrinol Metab 90:6678-6686
62. L. Cell 87:619-628
63. Liou JY, Lee S, Ghelani D, Matijevic-Aleksic N, Wu KK (2006) Protection of endothelial survival by peroxisome proliferator-activated receptor-δ mediated 14-3-3ε upregulation. Arterioscler Thromb Vasc Biol 26:1481-1487